# Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

> **NCT06619860** · PHASE2 · RECRUITING · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 300 (estimated)

## Conditions studied

- Diabetic Peripheral Neuropathic Pain

## Interventions

- **DRUG:** VX-993
- **DRUG:** Pregabalin
- **DRUG:** Placebo (matched to pregabalin)
- **DRUG:** Placebo (matched to VX-993)

## Key facts

- **NCT ID:** NCT06619860
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-18
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-05-30
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06619860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06619860, "Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06619860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*